ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

448

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions

OsteosarcomaSoft Tissue Sarcoma (STS)

Interventions

DRUG

HS-20093

HS-20093: administered as an IV infusion

DRUG

Anlotinib

Anlotinib: 12mg once daily (QD) orally

DRUG

Epirubicin

Epirubicin: administered as an IV infusion

DRUG

Adebrelimab

Adebrelimab: administered as an IV infusion

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY